Switching to nevirapine-based HAART in virologically-suppressed patients: influence of a longer twice-daily induction period on once-a-day dosing / Brandolini, M., Cattelan, A., Orani, A., Sighinolfi, L., Andreoni, M., Nardini, G., Sotgiu, G., Maserati, R.. - (2008). (9th International Congress on Drug Therapy in HIV infection Glasgow 2008, Nov 9-13).

Switching to nevirapine-based HAART in virologically-suppressed patients: influence of a longer twice-daily induction period on once-a-day dosing

SOTGIU, Giovanni;
2008-01-01

2008
Switching to nevirapine-based HAART in virologically-suppressed patients: influence of a longer twice-daily induction period on once-a-day dosing / Brandolini, M., Cattelan, A., Orani, A., Sighinolfi, L., Andreoni, M., Nardini, G., Sotgiu, G., Maserati, R.. - (2008). (9th International Congress on Drug Therapy in HIV infection Glasgow 2008, Nov 9-13).
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/67061
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact